Blog

/Blog

Bioanalytical Methods Transfer: Overcoming Data-sharing Challenges

by Roger Hayes, PhD

In a previous blog, I shared my perspective on best practices in bioanalytical methods transfer. Such practices aim to assure quality data across the drug development process. At the same time, they require a […]

By | 2017-07-04T10:27:27+00:00 January 20th, 2015|Blog|Comments Off on Bioanalytical Methods Transfer: Overcoming Data-sharing Challenges

Best Practices for Successful Bioanalytical Methods Transfer

By Roger Hayes, PhD

From bench to bedside, developing a new drug requires many years and many hands. Each step must be taken carefully to ensure the quality and integrity of the process. This is of special importance in bioanalytical methods transfer.

Method transfer involves seamlessly moving a bioanalytical process and the information it generates across different […]

By | 2017-07-04T10:27:27+00:00 January 14th, 2015|Blog|Comments Off on Best Practices for Successful Bioanalytical Methods Transfer

Reducing Clinical Failures through Early DMPK Studies

by Ric Slauter, PhD, DABT

Suppose a baseball team had a player whose batting average was a mere 0.0001. We can safely assume that player won’t last long.

Yet that average is the reality of drug development. Whereas 10,000 compounds might enter the discovery stage, only one is likely to survive to become a marketed medication, according […]

By | 2017-07-04T10:27:29+00:00 January 7th, 2015|Blog|Comments Off on Reducing Clinical Failures through Early DMPK Studies

Microsampling Offers Powerful Advantages

By Roger Hayes, PhD

The adage “a little goes a long way” is an emerging reality in preclinical drug development, where new techniques in micro-volume sample analysis are yielding advantages for drug developers.

Traditionally, sample sizes of blood, plasma or serum needed for toxicokinetic (TK) and pharmacokinetic (PK) analysis often exceeded what’s allowed when using rodents, especially […]

By | 2014-12-17T14:33:32+00:00 December 17th, 2014|Blog|Comments Off on Microsampling Offers Powerful Advantages

Finding the Right DMPK Partner

by Ric Slauter, PhD, DABT

The 20th century saw amazing, life-saving discoveries in medical research. That innovative spirit remains strong in the new century, even as it advances into more complex areas of study, more complicated diseases, and more rigorous standards. Finding a partner who expertly balances those dynamics is key to advancing drug development.

Today’s medical […]

By | 2017-07-04T10:27:33+00:00 December 17th, 2014|Blog|Comments Off on Finding the Right DMPK Partner

The Strongest Rope: Early PK-PD Modeling

by Ric Slauter, PhD, DABT

The strongest rope is one made of multiple cords woven tightly together. Likewise, applying the closely associated tools of pharmacokinetics and pharmacodynamics early in drug development can lift the best candidates above the also-rans.

While pharmacokinetics (PK) and pharmacodynamics (PD) have a strong relationship, they’ve been approached separately in the past: PK […]

By | 2017-07-04T10:27:34+00:00 December 17th, 2014|Blog|Comments Off on The Strongest Rope: Early PK-PD Modeling

Tracking Biodistribution with Molecular Imaging

by Scott Haller, MS

Medical advancements must bear scrutiny—including the presumed unlimited promise of stem cell-based therapies. Fortunately, that scrutiny is possible through many assays, including non-invasive imaging methods that provide crucial data on biodistribution of these potential new treatments.

Tracking the distribution and fate of implanted or transplanted stem cells is important to understanding where in […]

By | 2014-12-12T17:20:37+00:00 December 12th, 2014|Blog|Comments Off on Tracking Biodistribution with Molecular Imaging

Lessons Learned in Juvenile Toxicity Testing

by Ali Said Faqi

One area where this is especially true is juvenile toxicity testing. We know there are profound differences between adults and children in drug disposition and effect; yet most drugs prescribed to children have not been adequately studied in the young.

Fortunately, the pharmaceutical industry and regulatory agencies are starting to address this issue. […]

By | 2014-11-26T17:15:36+00:00 November 26th, 2014|Blog|Comments Off on Lessons Learned in Juvenile Toxicity Testing

Stem Cell-Derived RPE Cells Sharpen View of Retinal Disease

by Thomas Vihtelic, DVM, PhD
Director of Experimental Therapeutics, MPI Research

Advancing stem cell research is a rewarding part of our work at MPI Research. We also follow related scientific achievements, as these can enhance our own understanding and expertise. For example, two recent studies involving stem cells and retinal disease are providing valuable insights. […]

By | 2017-07-04T10:27:36+00:00 November 19th, 2014|Blog|Comments Off on Stem Cell-Derived RPE Cells Sharpen View of Retinal Disease

Partnership Prepares Next Generation of Animal Technicians

by April George, DVM

The value of animal research to advancing new medicines can’t be understated. Making sure the highest possible standards of animal welfare are upheld is a key element of that value—now and in the future.

At MPI Research, we insist on the best husbandry practices so that the animals in our care […]

By | 2014-10-28T14:05:27+00:00 October 6th, 2014|Blog|Comments Off on Partnership Prepares Next Generation of Animal Technicians